SeaSpine Reports Granting of Inducement Awards
SeaSpine Holdings Corporation (NASDAQ: SPNE) announced the issuance of inducement awards to seventeen non-executive employees on October 1, 2020. The awards include options to purchase 11,574 shares and restricted stock units for 21,769 shares of common stock. The exercise price of options is $14.41, equaling the closing price on the grant date. Options will vest fully after one year, while restricted stock units will vest in equal installments over three years. This initiative aligns with Nasdaq Marketplace Rule 5635(c)(4) and aims to attract new talent to SeaSpine.
- Issuance of inducement awards demonstrates commitment to attracting talent.
- The options have a favorable exercise price of $14.41, aligning with market conditions.
- None.
CARLSBAD, Calif., Oct. 02, 2020 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it has issued inducement awards to seventeen non-executive employees.
The awards were made on October 1, 2020 under SeaSpine’s 2020 Employment Inducement Equity Incentive Award Plan, which provides for the granting of equity awards to new employees of SeaSpine. The inducement awards consist of options to purchase 11,574 shares of SeaSpine common stock and restricted stock unit awards with respect to an aggregate of 21,769 shares of SeaSpine common stock. The exercise price of the options was
About SeaSpine
SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in both orthobiologic sciences and spinal implants product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide through a committed network of increasingly exclusive distribution partners.
Investor Relations Contact
Leigh Salvo
(415) 937-5402
ir@seaspine.com
FAQ
What inducement awards were issued by SeaSpine (SPNE) on October 1, 2020?
What is the exercise price of the inducement options for SeaSpine (SPNE)?
How do the restricted stock units vest for SeaSpine (SPNE) employees?